文献速递治疗药物监测与药物基因组学特殊人群用药

英夫利西单抗在≤10岁儿童炎症性肠病中的群体药代动力学:标签推荐剂量无法达到治疗目标浓度

Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration.
PubMed 文献 · Clin Pharmacokinet · 2025-10-29

该研究回顾性收集14个欧洲和加拿大中心2015-2019年≤10岁儿童炎症性肠病患者英夫利西单抗(IFX)治疗药物监测数据,建立群体药代动力学模型。结果显示≤10岁患儿IFX清除率高于年长儿童和成人,白蛋白和C反应蛋白可解释清除率个体间变异;标签推荐剂量下维持期约4周浓度低于5 mg/L,需4周给药间隔以维持谷浓度>5 mg/L。

要点

  • ≤10岁IBD患儿IFX清除率高于>10至<17岁儿童和成人。
  • 白蛋白和CRP可解释IFX清除率的个体间变异。
  • 标签推荐剂量下维持期约4周IFX浓度低于5 mg/L,需4周给药间隔。

核心结论

  • ≤10岁儿童IBD患者IFX清除率高于年长儿童和成人,白蛋白和CRP可解释清除率变异。
  • 不同IFX检测方法间的差异不影响总体药物暴露。
  • 为维持≤10岁患儿谷浓度>5 mg/L,需要4周给药间隔。

研究设计与样本

  • 回顾性收集14个欧洲和加拿大中心2015-2019年≤10岁儿童IBD患者IFX治疗药物监测数据。
  • 共纳入104例≤10岁儿童IBD患者,2150个IFX浓度,由6种不同IFX检测方法测定。
  • 采用NONMEM version 7.4非线性混合效应模型建立 refined 二室群体药代动力学模型,并对6个已发表群体药代动力学模型进行外部验证。

主要发现

  • 开始IFX治疗时人群中位(最小-最大)年龄为8.2岁(1.2-10.0),体重为25 kg(9.5-40.9)。
  • 外部验证中最佳模型rMPE为33.73%、rRMSE为1189.59%,所有已发表模型对该研究人群均不适用。
  • 典型清除率(最小-最大,L/day/65 kg)在≤10岁患儿为0.615-0.943,已发表>10至<17岁儿童为0.015-0.353,已发表成人为0.317-0.350。
  • 白蛋白和CRP均可解释清除率的个体间变异。
  • 残差误差模型按IFX检测方法分层后,Immundiagnostik与Shomron Ben-Horin开发的「in-house」检测方法间rPE差异有统计学意义(P<0.05),Caltag与in-house检测方法间rPE差异有统计学意义(P<0.05);Immundiagnostik与Sanquin检测方法间个体清除率事后估计值差异有统计学意义(P=0.033),但第6-14周估计AUC(AUCw6-14)相似(P>0.05)。

关键数值与推荐

  • ≤10岁儿童IBD患者维持谷浓度>5 mg/L需要4周给药间隔。
  • 已发表群体药代动力学模型外部验证最佳rMPE为33.73%、rRMSE为1189.59%,均不适用于≤10岁人群。

临床怎么用

  • ≤10岁儿童IBD患者使用IFX时应考虑比标签推荐更短的4周给药间隔以维持谷浓度>5 mg/L。
  • 解读IFX治疗药物监测结果时需注意不同检测方法间相对预测误差和个体清除率估计可能存在差异,但总体药物暴露相似。
  • 白蛋白和CRP可辅助解释IFX清除率个体间变异,支持个体化 dosing 评估。

局限性

  • 回顾性研究设计。
  • 仅纳入14个欧洲和加拿大中心2015-2019年数据。
  • 已发表群体药代动力学模型外部验证表现不佳,可能限制模型外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Younger patients with paediatric inflammatory bowel disease (IBD) may require higher infliximab (IFX) doses to attain similar target trough levels compared with older paediatric and adult patients with IBD. This study aimed to investigate the population pharmacokinetics (popPK) of infliximab (IFX) in young paediatric patients with inflammatory bowel disease (IBD) (≤ 10 years old), optimize the IFX dosage in this special population and explore whether different IFX assays were comparable. METHODS: IFX therapeutic drug monitoring (TDM) data from young paediatric patients with IBD (≤ 10 years old) were retrospectively collected from 14 European and Canadian centres (2015-2019). External validation of published popPK models was performed by calculating relative mean predictive errors (rMPE) and relative root mean square errors (rRMSE) to assess bias and imprecision. A refined popPK model was then developed using nonlinear mixed-effects modelling in NONMEM version 7.4. PopPK parameters in young paediatric patients with IBD (≤ 10 years old) were compared with those in published paediatric patients (> 10 to < 17 years) and adults. RESULTS: In total, 2150 IFX concentrations from 104 young paediatric patients with IBD (≤ 10 years old) were measured by six different IFX assays. The median (min-max) age and body weight at start of IFX treatment of the population was 8.2 years old (1.2-10.0) and 25 kg (9.5-40.9), respectively. For the external validation, six published popPK models were evaluated. The best-performing model showed values for rMPE and rRMSE at 33.73% and 1189.59%, which rendered all models inadequate for our study population. Subsequently, a refined two-compartmental popPK model was developed. Typical clearance (CL) values (min-max, L/day/65 kg) were 0.615-0.943 for paediatric patients ≤ 10 years, 0.015-0.353 for published paediatric patients (> 10 to < 17 years) and 0.317-0.350 for published adults. Both albumin and C-reactive protein (CRP) could explain the inter-individual variability obtained in CL. Stratifying for IFX assays in the residual error model showed significant differences in relative prediction errors (rPE) between Immundiagnostik and an assay developed by Shomron Ben-Horin (named "in-house" assay) (P < 0.05) and between Caltag and in-house assays (P < 0.05). Post hoc individual CL differed between the Immundiagnostik and Sanquin assays (P = 0.033), while estimated area under the curve for weeks 6-14 (AUCw6-14) remained similar (P > 0.05). With label-recommended dosing, IFX concentrations dropped below 5 mg/L for approximately 4 weeks during maintenance. CONCLUSIONS: Paediatric patients ≤ 10 years, demonstrated a higher IFX CL than paediatric patients > 10 to < 17 years and adults, with albumin and CRP explaining the variability of CL. The differences obtained across the IFX assays did not affect overall drug exposure. To maintain trough concentrations above 5 mg/L in paediatric patients ≤ 10 years, a dosing interval of 4 weeks is required.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Zhao Q, Jongsma MME, Vuijk SA, et al. Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration. Clin Pharmacokinet. 2025. PMID: 41160254. doi:10.1007/s40262-025-01565-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。